Purpose: To evaluate the usefulness of vascular phase images of contrast-enhanced ultrasonography (CE-US) with Sonazoid for hepatocellular carcinomas (HCCs), a retrospective, comparative study was conducted of images of HCCs obtained by CE-US and superparamagnetic iron oxide (SPIO) magnetic resonance imaging (MRI) and evaluated qualitatively and quantitatively. Methods: Seventy-seven patients with 88 HCCs who received CE-US and SPIO-MRI were reviewed. The ratio of the echogenicity of the tumor and nontumor areas was calculated with postvascular phase CE-US (postvascular phase ratio). The ratio of the intensity of the nontumor to tumor areas on SPIO-enhanced MRI (SPIO intensity index) was also calculated. The Pearson correlations were calculated for all values between the postvascular phase ratio and SPIO intensity index for quantitative comparison. These images were also compared qualitatively for the detection rate of the tumors. Results: The sensitivities of CE-US and SPIO-MRI in detecting tumors were 98 and 95%, respectively (nonsignificant, χ2 test). The postvascular phase ratio correlated with the SPIO intensity index for HCCs (Pearson r = 0.803, p < 0.05). The image conformity of the result from the liver parenchymal phase CE-US and SPIO-MRI was 92%. Dedifferentiation spots of nodule-in-nodule HCCs were detected in 4 (80%) of 5 on postvascular phase images of CE-US, and in 2 (40%) of 5 on SPIO-MRI (nonsignificant, χ2 test). Conclusions: Postvascular phase images of CE-US with Sonazoid appear promising as an alternative to SPIO-enhanced MRI. Further study cases are needed to confirm the usefulness of postvascular phase images of CE-US compared to SPIO-MRI for the detection of dedifferentiation foci in hepatic tumors.

Keywords:
Contrast-enhanced ultrasonography, Postvascular phase, Superparamagnetic iron oxide magnetic resonance imaging, Hepatocellular carcinoma
1.
Quaina E, Blomley MJ, Patel S, et al: Initial observation on the effect of irradiation on the liver-specific uptake of Levovist. Eur J Radiol 2002;41:192–199.
2.
Lim AK, Patel N, Eckersley RJ, et al: Evidence for spleen-specific uptake of a microbubble contrast agent: a quantitative study in healthy volunteers. Radiology 2004;231:785–788.
3.
Blomley MJ, Albrecht T, Cosgrove DO, et al: Stimulated acoustic emission to image a late liver and spleen-specific phase of Levovist in normal volunteers and patients with and without liver disease. Ultrasound Med Biol 1999;25:1341–1352.
4.
Yanagisawa K, Moriyasu F, Miyahara T, et al: Phagocytosis of ultrasound contrast agent microbubles by Kupffer cells. Ultrasound Med Biol 2007;33:318–325.
5.
Saini S, Stark DD, Hahn PF, Bousquet JC, Introcasso J, Wittenberg J, et al: Ferrite particles: a superparamagnetic MR contrast agent for enhanced detection of liver carcinoma. Radiology 1987;162:217–222.
6.
Stark DD, Weissleder R, Elizondo G, Hahn PF, Saini S, Todd LE, et al: Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988;168:297–301.
7.
Mergo PJ, Ros PR: Benign lesions of the liver. Radiol Clin North Am 1998;36:319–331.
8.
Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al: Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205–212.
9.
Sontum PC, Osten J, Drystad K, et al: Acoustic properties of NC100100 and their relation with the microbubble size distribution. Invest Radiol 1999;34:268–275.
10.
Kudo M: New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma. Hepatol Res 2007;37(suppl 2):S193–S199.
11.
Inoue T, Kudo M, Watai R, et al: Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2005;40: 1139–1147.
12.
Hatanaka K, Kudo M, Minami Y, et al: Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51(suppl):59–67.
13.
Watanabe R, Matsumura M, Munemasa T, et al: Mechanism of hepatic parenchema-specific contrast of microbubble-based contrast agent for ultrasonography. Invest Radiol 2007;42:643–651.
14.
Kojiro M: ‘Nodule-in-nodule’ appearance in hepatocellular carcinoma: its significance as a morphologic marker of dedifferentiation. Intervirology 2004;47:179–183.
15.
Kudo M: Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis 1999;19:297–309.
16.
Kudo M: Contrast-Enhanced Harmonic Imaging of Hepatic Tumors. Tokyo, Igakusyoin, 2001.
17.
Elizondo G, Weissleder R, Stark DD, et al: Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797–801.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.